Search Results
Mar 11, 2026, 03:16 ET 보타, 바이오 제조를 위한 피지컬 AI 플랫폼 사이온 AI 출시
입증하며 AI 사이언티스트(AI Scientist) 시스템으로서의 역량을 검증했다.주요 결과문헌 이해: LitQA+SuppQA에서 70.7% — 주요 범용 모델을 상회서열 추론: DNA, RNA, 단백질 작업을 포함한 SeqQA에서 88.2%유전공학: 유전자 편집 및 클로닝 벤치마크에서 84.9%과학적 발견: BAIS-SD 벤치마크에서 89.6%실제 환경 검증 결과, 사이온 AI는 문헌 검토부터 웻랩(wet-lab)
More news about: Bota
Mar 10, 2026, 18:08 ET Bota Launches SAION AI -- Physical AI Platform for Biomanufacturing
Literature Comprehension: 70.7% on LitQA+SuppQA — surpassing leading general-purpose modelsSequence Reasoning: 88.2% on SeqQA across DNA, RNA and protein tasks.Genetic Engineering: 84.9% on gene editing and cloning benchmarks.Scientific Discovery: 89.6% on BAIS-SD benchmark.Real-world
More news about: Bota
Mar 10, 2026, 17:51 ET 讓智能在實驗中進化：恩和科技發布 SAION AI - 面向生物制造的物理智能平台
65.0%）。生物序列分析 在 SeqQA (Lab-Bench) 基准測試准確率達到88.2% ，領先當前主流基座模型，超過公開評測成績斯坦福大學文獻中發表的 Biomni平台 （81.9%），展現出領先的 DNA / RNA / 蛋白序列推理與設計能力。科學發現與推理 在 BAIS-SD 基准（評估智能體是否具備生成生物科學新發現與推理的能力）測試達到89.6%准確率，相比主流基准模型提升約12個百分點，體現出其在科研假設理解、科學推理和研究發現任務中的領先能力。真實實驗驗證
More news about: Bota
Mar 10, 2026, 17:33 ET Bota Launches SAION AI -- Physical AI Platform for Biomanufacturing
Literature Comprehension: 70.7% on LitQA+SuppQA — surpassing leading general-purpose modelsSequence Reasoning: 88.2% on SeqQA across DNA, RNA and protein tasks.Genetic Engineering: 84.9% on gene editing and cloning benchmarks.Scientific Discovery: 89.6% on BAIS-SD benchmark.Real-world
More news about: Bota
Mar 10, 2026, 12:35 ET AcuraStem Awarded Target ALS Grant to Advance Therapeutics Targeting a Core Driver of ALS
Hopkins University), and Wilfried Rossoll, Ph.D. (Mayo Clinic Jacksonville). These collaborations unite complementary strengths in TDP-43–dependent RNA splicing and fluid biomarker development (Wong lab) with cutting-edge proteomics and neuroproteostasis expertise focused on TDP-43 proteinopathy (Rossoll
More news about: AcuraStem - Patient-Based Therapeutics
Mar 10, 2026, 10:25 ET Skyhawk Therapeutics Appoints Aaron Deves as Chief Commercial Officer to Lead Commercialization of SKY-0515 for Huntington's Disease
2026 /PRNewswire/ -- Skyhawk Therapeutics, Inc., a clinical-stage biotechnology company developing novel small molecule therapies to modulate critical RNA targets for a series of challenging neurological diseases, announces the appointment of Aaron Deves as Chief Commercial Officer. Mr. Deves brings more
More news about: Skyhawk Therapeutics
Mar 10, 2026, 10:02 ET Skyhawk Therapeutics Appoints Aaron Deves as Chief Commercial Officer to Lead Commercialization of SKY-0515 for Huntington's Disease
2026 /PRNewswire/ -- Skyhawk Therapeutics, Inc., a clinical-stage biotechnology company developing novel small molecule therapies to modulate critical RNA targets for a series of challenging neurological diseases, announces the appointment of Aaron Deves as Chief Commercial Officer. Mr. Deves brings more
More news about: Skyhawk Therapeutics
Mar 10, 2026, 09:00 ET Co-Diagnostics Regains Compliance with Nasdaq Listing Requirements
technologies. The Company's technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR at-home and point-of-care platform (subject to regulatory
More news about: Co-Diagnostics
Mar 10, 2026, 05:59 ET EQT Foundation opens applications for science grants to overcome the blood-brain barrier and transform CNS drug delivery
engineering, alternative viral vectors, non-viral systems such as lipid or polymeric nanoparticles, bispecific antibodies, antibody-drug conjugates, and RNA platforms with demonstrated or plausible brain penetrationBBB models, biomarkers, and translational tools: human-relevant in vitro BBB models,
More news about: EQT
Mar 09, 2026, 22:08 ET SBMAコミュニティを活性化させる：AnnJi、2026年KDA会議で患者・家族フォーラムに重点を置き、AJ201の科学的進歩を報告
トランスクリプトミクスの知見：「SBMA筋におけるAJ201標的結合および生物学的応答のトランスクリプトミクス証拠（Transcriptomic Evidence of AJ201 Target Engagement and Biological Response in SBMA Muscle）」 と題する研究では、RNA-seqを利用し、AJ201がNrf2抗酸化経路に関与することを実証した。 本データは、治療が単一の経路ではなく複数の生物学的軸を調節することを確認し、AJ201の薬剤特異的な生物学的関与を裏付けた。第3相臨床試験設計： AnnJiは、国際多施設共同第3相臨床試験の
More news about: AnnJi Pharmaceutical Co., Ltd.
Mar 09, 2026, 11:07 ET PrimeC Long-Term Survival Data to Be Presented at a Leading ALS Scientific Conference
target several key mechanisms of ALS and AD, that contribute to neuron degeneration, inflammation, iron accumulation and impaired ribonucleic acid ("RNA") regulation to potentially inhibit the progression of ALS and AD.About ALSAmyotrophic lateral sclerosis ("ALS") is an incurable
More news about: NeuroSense
Mar 09, 2026, 08:00 ET ITF Therapeutics LLC Presents New Data and Analyses on Givinostat for Treatment of Duchenne Muscular Dystrophy at 2026 MDA Clinical and Scientific Conference
enzymes regulate these pathogenic stromal responses and their inhibition restores homeostatic conditions. This poster reports findings from integrated RNA-seq and ATAC-seq analyses to define how givinostat modulates TGFβ-induced fibrotic programs in DMD-derived FAPs and SMFs.Encore poster presentations
More news about: ITF Therapeutics LLC
Mar 09, 2026, 06:00 ET IDEAYA Biosciences Announces First-Patient-In for Phase 1 Trial of IDE892, a Potential Best-In-Class PRMT5 Inhibitor for MTAP-Deleted Solid Tumors, and Provides MTAP and CDKN2A Pipeline Update
MTAP leads to the accumulation of methylthioadenosine (MTA) and increased dependence on PRMT5 and MAT2A, two key enzymes involved in methylation and RNA splicing. In MTAP-deleted tumors, this biology establishes a robust synthetic lethal vulnerability that underpins the mechanistic rationale for combining
More news about: IDEAYA Biosciences, Inc.
Mar 06, 2026, 12:37 ET Ausgründung von Novigenix AI soll KI-gestützte Immunintelligenz beschleunigen
Immunintelligenz-Plattform, die aus einfachen Blutproben die systemische Immunantwort längsschnittlich entschlüsselt. Durch die Analyse der vom Immunsystem stammenden RNA mithilfe von fortschrittlichem maschinellem Lernen verwandelt die Plattform komplexe Flüssigbiopsiedaten in klinisch verwertbare Erkenntnisse. Die Plattform
More news about: Novigenix AI
Mar 06, 2026, 06:02 ET 15 Top Press Releases from February
new class of therapeutics utilizing engineered circular RNA paired with novel lipid nanoparticles to allow the patient's own body to generate cell therapies that can treat underlying disease. Experiments to date suggest that Orna's circular RNA platform may deliver more durable expression of therapeutic
More news about: PR Newswire
Mar 05, 2026, 20:50 ET Befähigung der SBMA-Gemeinschaft: AnnJi hebt das Patienten- und Familienforum hervor und stellt den wissenschaftlichen Fortschritt von AJ201 auf der KDA-Konferenz 2026 vor
Biological Response in SBMA Muscle" (Transkriptomischer Nachweis von AJ201 Target Engagement und biologischer Reaktion im SBMA-Muskel) nutzte RNA-seq, um zu zeigen, dass AJ201 den Nrf2-Antioxidations-Signalweg einschaltet. Die Daten bestätigten, dass die Behandlung mehrere biologische Achsen und
More news about: AnnJi Pharmaceutical Co., Ltd.
Mar 05, 2026, 14:52 ET Herpes Virus Fluidizes Cell Nuclei to Multiply Faster
looking to see if this mechanism is used by other viruses that replicate in the nucleus, from the double-stranded DNA viruses responsible for shingles to RNA viruses like influenza virus to retroviruses like HIV."Along with Dr. Holt and Dr. Herzog, authors of the study from NYU Langone were Tong Shu,
More news about: NYU Langone
Mar 05, 2026, 12:25 ET Shared origins illuminate potential dependency across brain tumor types
cohort of rare tumor samples from 38 patients and compared it to normal pineal gland development. By measuring gene expression using single-cell RNA-sequencing, they found that a population of early cells called pinealocyte progenitors is the most similar to these tumors, implicating their role in pineoblastoma
More news about: St. Jude Children's Research Hospital
Mar 05, 2026, 08:00 ET Therna Announces Collaboration with Charles River to Advance Single-Patient Personalized RNA Therapeutics
available treatment options.About Therna BiosciencesTherna is a biotechnology company redefining RNA therapeutics by uniting deep RNA biology with state-of-the-art RNA foundation models and generative AI. Its biology-guided platform enables rapid, end-to-end design of precisely engineered
More news about: Therna Biosciences
Mar 05, 2026, 07:00 ET Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
early-stage programs encompass a wide range of technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue.Headquartered in Bridgewater, New Jersey, Insmed has offices and research locations throughout the United States,
More news about: Insmed Incorporated
Mar 05, 2026, 03:00 ET Novigenix AI Spin-Out to Accelerate AI-Powered Immune Intelligence
AI-powered immune intelligence platform designed to decode the systemic immune response longitudinally from simple blood samples. By analyzing immune-derived RNA using advanced machine learning, the platform transforms complex liquid biopsy data into clinically actionable insights. The platform supports tracking
More news about: Novigenix AI
Mar 04, 2026, 21:01 ET Empowering the SBMA Community: AnnJi Highlights Patient & Family Forum and Shares AJ201 Scientific Advancement at the 2026 KDA Conference
Transcriptomic Insights: Research titled "Transcriptomic Evidence of AJ201 Target Engagement and Biological Response in SBMA Muscle" utilized RNA-seq to demonstrate that AJ201 engages the Nrf2 antioxidant pathway. The data confirmed that treatment modulates multiple biological axes rather than
More news about: AnnJi Pharmaceutical Co., Ltd.
Mar 04, 2026, 20:31 ET Empowering the SBMA Community: AnnJi Highlights Patient & Family Forum and Shares AJ201 Scientific Advancement at the 2026 KDA Conference
Transcriptomic Insights: Research titled "Transcriptomic Evidence of AJ201 Target Engagement and Biological Response in SBMA Muscle" utilized RNA-seq to demonstrate that AJ201 engages the Nrf2 antioxidant pathway. The data confirmed that treatment modulates multiple biological axes rather than
More news about: AnnJi Pharmaceutical Co., Ltd.
Mar 04, 2026, 18:01 ET Global Nanomedicine Market is Projected to Cross the USD 550 Billion Mark by 2034 as Advanced Drug Delivery Technologies Accelerate Adoption | DelveInsight
Developmental Activities in the Nanomedicine MarketIn February 2026, scientists at Newark developed a first-of-its-kind RNA-based nanotechnology that assembles itself inside living human cells and can be programmed to stop the propagation of harmful cells. The findings, recently
More news about: DelveInsight Business Research, LLP
Mar 04, 2026, 17:46 ET H. pylori Infections Market in the 6MM to Observe Stupendous Growth at a CAGR of 9.5% During the Forecast Period (2026-2036) | DelveInsight
quadruple therapy, including in antibiotic-resistant strains. Its differentiation lies in a single-molecule dual mechanism combining rifamycin-mediated RNA polymerase inhibition with nitroimidazole-induced DNA damage, providing intrinsic synergy, greater potency, and lower resistance risk without added regimen
More news about: DelveInsight Business Research, LLP